16-17 September 2015, Marriott Regents Park Hotel, London UK
SMi presents the 4th annual conference on Cancer Vaccines 2015
The 4th annual Cancer Vaccines conference 2015 will strengthen knowledge of targeted immunotherapies taking the foreground in revolutionizing cancer vaccines as well as look at the practicalities towards achieving sustained immune response.Understanding personalized cancer treatment will be a major focus, as will hearing from a selection of biotechs and industry pioneers at the forefront of vaccine development.
SMi Group have worked closely with a leading panel of experts such as GSK Vaccines, Vaccinogen, The National Cancer Institute and Kings College London, to create a programme that will expand scientific horizons in topics such as formulation development, tumour genetic heterogeneity, fully personalised cancer treatment, combination therapies, gene editing for immunotherapy, plus much more!
Featured Speakers Include:
Professor Farzin Farzaneh, Professor of Molecular Medicine, Kings College London
Michael Hanna, Chairman and CEO, Vaccinogen
Derek O’Hagan, Global Head of Vaccine Chemistry and Formulation, GSK
Sebastian Kreiter, VP Immunotherapy, BioNTech RNA Pharmaceuticals
Vaios Karanikas, Biomarker & Experimental Medicine Leader, Tumor Immunology, Roche
Thomas Felzmann, CEO, Activartis Biotech GmbH
Peter L. Andersen, VP Vaccine R&D, Statens Serum Institut
Ravi A. Madan, Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute
Professor Dr. Dirk Jager, Medical Oncology, National Center for Tumor Diseases, University Hospital Heidelberg
Reasons to Attend:
Address the provocative issue of tumour genetic heterogeneity in immunotherapy
Understand the angiogenic process in both normal and tumour and development
Gain key industry perspective in combination therapies to advance immune-oncology vaccines and enhance patient outcomes
Envision RNA - vaccinology for building the next-generation of RNA immunogens
Immerse yourself into a universe of new insights as we explore cutting edge developments in areas such as CAR T-Cell Therapy, Oncolytic viral therapies, Gene-therapy and Adoptive T-Cell transfer
To register or for further information, visit the conferences website.
Alternatively contact the team on +44 (0)870 9090 712 or email firstname.lastname@example.org
Dr. Andreas Kessell
Managing Director, Co-Founder
"Search, order, apply – we support you in all areas."